Fosphenytoin

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 6, 2009, Pages 695-701

  Kai, Eriksson ^a   Tapani, Keränen ^b   Reetta, Kälviäinen ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Epilepsy; Fosphenytoin; Health economics; Phenytoin; Repetitive seizures; Status epilepticus; Voltage sensitive Na+ channels

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; HARKOSERIDE; LORAZEPAM; ORGANOPHOSPHATE; PHENOBARBITAL; PHENYTOIN; PHENYTOIN DERIVATIVE; SODIUM CHANNEL; VALPROIC ACID;

ALLERGIC REACTION; ANTICONVULSANT ACTIVITY; ATAXIA; BLOOD PRESSURE; BRADYDYSRHYTHMIA; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONSCIOUSNESS DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERPHOSPHATEMIA; HYPOTENSION; IDIOPATHIC COMPLEX PARTIAL SEIZURE; INFUSION RATE; INJECTION SITE EDEMA; INJECTION SITE NECROSIS; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LIVER TOXICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICATION ERROR; METABOLIC ENCEPHALOPATHY; MYOCLONUS EPILEPSY; NYSTAGMUS; PANCREATITIS; PATIENT MONITORING; PERIPHERAL EDEMA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PURPLE GLOVE SYNDROME; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; REVIEW; SEIZURE; SOMNOLENCE; SYMPTOMATIC EPILEPSY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ANTICONVULSANTS; CHILD; HUMANS; PHENYTOIN; PRODRUGS; SEIZURES;

EID: 67649366404     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902997975     Document Type: Review

References (45)

1. Chang BS, Lowenstein DH. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60(1):10-16
2. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999;91(4):593-600 (Pubitemid 30133456)
3. Beghi E. Overview of studies to prevent posttraumatic epilepsy. Epilepsia 2003;44(Suppl 10):21-26 (Pubitemid 37280389)
4. Kälviäinen R. Status epilepticus treatment guidelines. Epilepsia 2007;48(Suppl 8):99-102 (Pubitemid 350045540)
5. Appleton R, Sweeney A, Choonara I, et al. Lorazepam versus Diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 1995;37:682-688
6. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev 2008; Issue 3. Art. No.: CD001905
7. Metsäranta P, Koivikko M, Peltola J, Eriksson K. Outcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality. Dev Med Child Neurol 2004;46(1):4-8 (Pubitemid 38120444)
8. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-798 •• First comparative study of first- and second-line AED treatments in convulsive status epilepticus.
9. Stern JM, Perucca E, Browne TR. Phenytoin, fosphenytoin and other hydantoins. In: Engel J Jr, Pedley TA, editors, Epilepsy: a comprehensive textbook. Lippincott, Williams & Wilkins: Philadelphia, USA; 2008. p. 1609-1628
10. Baulac M. Phenobarbital and other barbiturates: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors, Antiepileptic drugs. 5th edition. Philadelphia (PA): Lippincott Williams and Wilkins; 2002. p. 515-521
11. Kokwaro G, Ogutu S, Muchohi S, et al. Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions. J Clin Pharmacol 2003;56:453-457 (Pubitemid 37188142)
12. Kälviäinen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus. A guide to treatment. CNS Drugs 2005;19(9):759-768
13. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001;35:1465-1470 (Pubitemid 33042083)
14. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000;41(10):1342-1345 (Pubitemid 30766162)
15. Yu K-T, Mills S, Thompson N, et al. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003;44(5):724-726 (Pubitemid 36554643)
16. Beydoun AA, Farrell K, Nasreddine WM. Valproate. In: Engel J Jr, Pedley TA, editors, Epilepsy: a comprehensive textbook. Lippincott, Williams & Wilkins: Philadelphia, USA; 2008. p. 1673-1681
17. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47(7):1128-1135 (Pubitemid 44086747)
18. Knake S, Gruener J, Hattemer K, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008;79(5):588-589 (Pubitemid 351571881)
19. Ruegg S, Naegelin Y, Hardmeier M, et al. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008;12(3):477-480
20. Krauss G, Ben-Menachem E, Mameniskiene R, et al. Intravenous lacosamide as replacement for oral lacosamide in subjects with partial-onset seizures: a multicenter, open-label, inpatient safety and tolerability trial [abstract]. Neurology 2007;68(Suppl 1):A125
21. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49(3):418-424 (Pubitemid 351294527)
22. Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9(1):33-42
23. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996;46(6 Suppl 1):S3-7 (Pubitemid 26185754)
24. Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003;42:33-58 •• Modern review of pharmacokinetics of fosphenytoin. (Pubitemid 36092257)
25. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S2-10 (Pubitemid 29484583)
26. Tunnicliff G. Basis of the antiseizure action of phenytoin. Gen Pharmacol 1996;27:1091-1097 (Pubitemid 26375420)
27. Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients. Neurology 1990;40:456-460 (Pubitemid 20117528)
28. Jamerson BD, Donn KH, Dukes GE, et al. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans. Epilepsia 1990;31:592-597 (Pubitemid 20310821)
29. Browne TR. Fosphenytoin (Cerebyx). Clin Neuropharmacol 1997;20:1-12
30. Browne TR, Davoudi H, Donn KH, et al. Bioavailability of ACC-9653 (phenytoin prodrug). Epilepsia 1989;30(Suppl 2):S27-32 (Pubitemid 19231525)
31. Hussey EK, Dukes GE, Messenheimer JA, et al. Evaluation of the pharmacokinetic interaction between diazepam and ACC-9653 (a phenytoin prodrug) in healthy male volunteers. Pharm Res 1990;71:1172-1176
32. Pellock JM. Fosphenytoin use in children. Neurology 1996;46(6 Suppl 1):S14-6 (Pubitemid 26185756)
33. Aweeka FT, Gottwald MD, Gambertoglio JG, et al. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease. Epilepsia 1999;40:777-782 (Pubitemid 29260719)
34. Cranford RE, Leppik IE, Patrick B, et al. Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology 1978;28:874-880 • Significant historical paper assessing the pharmacokinetics of iv. phenytoin. (Pubitemid 8390039)
35. Takeoka M, Krishnamoorthy KS, Soman TB, Caviness VS Jr. Fosphenytoin in infants. J Child Neurol 1998;13(11):537-540 (Pubitemid 29029806)
36. Kriel RL, Cifuentes RF. Fosphenytoin in infants of extremely low birth weight. Pediatr Neurol 2001;24:219-221 (Pubitemid 32294272)
37. Ogutu BR, Newton CRJC, Muchohi SN, et al. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. Br J Clin Pharmacol 2003;56:112-119 (Pubitemid 36886496)
38. Adams BD, Buckley NH, Kim JY, Tipps LB. Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. J Emerg Med. 2006 Jan;30(1):75-79 • Alarming report of unexpected side effects related to fosphenytoin. (Pubitemid 43129882)
39. McBryde KD, Wilcox J, Kher KK. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient. Pediatr Nephrol 2005;20(8):1182-1185 (Pubitemid 41001566)
40. ISMP Medication Safety Alert! January 27, 1999. Available from: www.ismp.org/Newsletters/acutecare/articles/19990127.asp
41. Taylor K, Paparella S. Fatal errors with cerebyx. J Emerg Nurs 2008;34(5):460-461
42. Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res 2002;24(8):842-848 (Pubitemid 35425132)
43. Horowitz BZ. Fosphenytoin farewell? Ann Emerg Med 2004;43(3):398-400.
44. Unstable bradydysrhythmias. J Emerg Med 2006;30(1):75-79
45. Rudis MI, Touchette DR, Swadron SP, et al. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med 2004;43(3):386-397 (Pubitemid 38282651)